Many times, companies become profitable based on one product they make. Nothing reflects this like Dyax Corp (NASDAQ: DYAX), which has seen its stock climb in value in the days following the FDA approval of its drug, Kalbitor. The drug is used for the treatment of hereditary angioedema (HAE).
Dyax is a fully integrated bio-pharmaceutical company focused on the discovery, development, and commercialization of novel therapies for unmet medical needs. Its key value drivers are Kalbitor and its Licensing and Funded Research Program (LFRP). Since Kalbitor was approved, the company has been selling it in the United States for the treatment of acute attacks of hereditary blood disorder that causes episodic attacks of swelling that may affect the face, genitals, gastrointestinal tract and upper airways. Outside the United States, the company has established partnerships to obtain regulatory approval for and commercialization on the drug.
In its 2012 third quarter report, total revenues increased to $13.1 million, compared with $10.1 million for the comparable quarter in 2011. Net sales for Kalbitor in the quarter were $10.8 million, compared to $6.6 million for 2011. Total revenue for the nine months ended September 30, 2012 was $38.6 million, compared with $40.2 million for same period in 2011. Research and development expenses for the third quarter 2012 were $6.2 million, as compared to $8.7 million for the comparable quarter in 2011. The lower research and development expenses during the third quarter 2012 were related to lower clinical trial costs. For the quarter ended September 30, 2012, the company reported a net loss of $5.2 million, as compared with a net loss of $9.7 million for the comparable quarter in 2011.
“The continued growth of Kalbitor sales demonstrate the importance of this novel therapy to the hereditary angioedema community and the value of our innovation and comprehensive patient service and support programs,” stated Gustav Christensen, The CEO of Dyax. “Further, our experiences in the HAE market gives us the insight with which to build a next generation of products and services.”
The company is not resting on its achievements. It is currently developing products to expand its angioederman portfolio, including a diagnostic strategy to conduct deeper study into the hereditary problem. It is also working on a portfolio of product candidates in various stages of clinical development. Its competitors are Shire PLC (NASDAQ: SHPG), ViroPharma (NASDAQ: VPHM), and CSL Behring, a privately held company. However, trading around $3 per share and having a market capitalization of around $337 million, Dyax has remained competitive. Put this company on your watch list. It could become good investment in future.